Post-exposure prophylaxis for HIV infection
Author:
- 1 April 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 9 (4) , 431-442
Abstract
Post-exposure prophylaxis (PEP) with antiretrovirals is now widely used worldwide after either occupational contact (with blood or another blood-containing fluid), or nonoccupational contact (mainly sexual or injection-drug use). It is assumed to reduce the risk of HIV transmission by at least 80%, although its efficacy has not been completely proven. Several countries have issued guidelines to help the clinician in their decision to offer PEP and to improve its cost-effectiveness. This article reviews the different antiretroviral combinations used, their safety profile, the recommendations and indications of PEP. The initial evaluation of an exposed individual is presented, as well as the follow-up during and after treatment.Keywords
This publication has 70 references indexed in Scilit:
- Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/LamivudineAntiviral Therapy, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Protection of Rhesus Macaques from Vaginal Infection by Vaginally Delivered Maraviroc, an Inhibitor of HIV‐1 Entry via the CCR5 Co‐ReceptorThe Journal of Infectious Diseases, 2010
- Use of Non-Occupational Post-Exposure Prophylaxis does not Lead to an Increase in High Risk Sex Behaviors in Men Who have Sex with Men Participating in the EXPLORE TrialAIDS and Behavior, 2010
- Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAARTAIDS, 2010
- Effect of Menses on Clearance of Y-Chromosome in Vaginal Fluid: Implications for a Biomarker of Recent Sexual ActivitySexually Transmitted Diseases, 2010
- Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical CourseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Estimation of HIV Incidence in the United StatesJAMA, 2008
- Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 TrialPLOS Medicine, 2005